Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

As fired and retired scientists rallied outside in the Atlanta heat, an advisory panel that Robert F. Kennedy Jr. handpicked ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines ...

the very first presentation it heard from CDC scientists involved the safety of the COVID-19 vaccine, particularly for pregnant women, infants and children. CDC studies found “no increased risk” that ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

Perhaps the most important thing President Trump did during his first term was to invest in Operation Warp Speed, which gave us mRNA-based Covid-19 vaccines in time to save millions of lives here and ...